MPO and ganglioneuroma: Unlike other autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, which have seen significant advances in incorporating emerging biological therapies, MPO-ANCA GN remains dependent on older non-specific treatments.